{"product_id":"lonza-pestle-analysis","title":"Lonza Group PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Competitive Advantage Starts with This Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eNavigate the forces reshaping Lonza Group with our concise PESTLE snapshot—covering regulatory, economic, technological, and environmental drivers that affect growth and risk exposure; buy the full PESTLE for a detailed, actionable roadmap to inform investment or strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Trade Dynamics and the BIOSECURE Act\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe United States BIOSECURE Act, implemented by late 2025, restricts federal contracts with select Chinese biotech firms, reshaping CDMO competition and driving Western sponsors to diversify suppliers; Lonza, with 2025 revenue ~CHF 5.8bn and ~40% manufacturing footprint in Switzerland and the US, is well-positioned to capture redirected demand. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSwiss-EU Bilateral Relations and Market Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of end-2025, unresolved Swiss-EU Institutional Framework talks remain critical for Lonza, with potential effects on access to the EU market that accounted for ~45% of its 2024 revenue of CHF 5.8bn. Changes could alter free movement of skilled biotech staff—nearly 38% of Lonza’s workforce in Switzerland—and mutual recognition of GMP standards, risking additional technical barriers and administrative delays for exports of high-value biologics across Europe. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Reform and Drug Pricing Legislation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical pressure to cut healthcare costs, exemplified by the Inflation Reduction Act which enables Medicare drug price negotiations projected to save up to $100 billion through 2031, is reshaping R\u0026amp;D priorities for Lonza’s clients.\u003c\/p\u003e\n\u003cp\u003ePricing caps risk compressing pharma margins but drive outsourcing: global CDMO spend reached about $87 billion in 2024, benefitting specialists like Lonza.\u003c\/p\u003e\n\u003cp\u003eLonza must pivot services toward therapeutic areas with resilient reimbursement and offer cost-efficient cell \u0026amp; gene and mRNA manufacturing to retain client demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNationalistic Industrial Policies for Essential Medicines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernments are funding onshoring of essential medicine production—EU and US initiatives allocated over $30bn in 2024–25 to boost domestic API and vaccine capacity—benefiting contract manufacturers like Lonza that can execute specialized projects with national partners.\u003c\/p\u003e\n\u003cp\u003eLonza’s capacity to engage in state-backed deals reduces exposure to protectionist trade barriers; public-private contracts and infrastructure subsidies have supported multi-year agreements, often improving revenue visibility and capital deployment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024–25 public funding \u0026gt; $30bn for domestic pharmaceutical capacity\u003c\/li\u003e\n\u003cli\u003eState-backed multi-year contracts increase revenue visibility\u003c\/li\u003e\n\u003cli\u003eSubsidies de-risk capital-intensive plant builds for Lonza\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Regulatory Harmonization for Advanced Therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe political push for harmonized cell and gene therapy standards, led by agencies like FDA and EMA aligning guidances, supports Lonza’s expansion in advanced medicines by enabling standardized processes across its 35+ global sites; recent FDA-EMA pilot initiatives cut cross-border approval discrepancies by ~20% (2024), shortening time-to-market.\u003c\/p\u003e\n\u003cp\u003eThis cooperation helps Lonza leverage its specialized platforms and reported 2024 advanced therapies revenue of CHF ~1.2bn, reinforcing first-mover advantages in contract manufacturing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA-EMA alignment reduced approval discrepancies ~20% (2024)\u003c\/li\u003e\n\u003cli\u003eLonza: 35+ global sites for standardized manufacturing\u003c\/li\u003e\n\u003cli\u003eAdvanced therapies revenue ~CHF 1.2bn (2024)\u003c\/li\u003e\n\u003cli\u003eHarmonization shortens time-to-market, boosts first-mover ROI\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolicy shifts and $30B onshoring boost Lonza’s CDMO lead—CHF5.8bn revenue, 35+ sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical shifts—US BIOSECURE Act (late‑2025), ongoing Swiss‑EU talks, IRA pricing reforms and \u0026gt;$30bn 2024–25 onshoring funds—reshape CDMO demand and favor Lonza (2025 revenue ~CHF 5.8bn; 2024 advanced therapies ~CHF 1.2bn; ~40% manufacturing in CH\/US; 35+ sites; ~45% revenue EU exposure).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 revenue\u003c\/td\u003e\n\u003ctd\u003e~CHF 5.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvanced therapies (2024)\u003c\/td\u003e\n\u003ctd\u003e~CHF 1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing footprint CH\/US\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU revenue exposure (2024)\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal sites\u003c\/td\u003e\n\u003ctd\u003e35+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic onshoring funds (2024–25)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$30bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect the Lonza Group across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends and forward-looking insights to identify threats, opportunities, and strategic responses for executives, investors, and advisors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented PESTLE summary of Lonza Group that teams can drop into presentations or planning sessions for quick alignment on external risks and market positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech Funding Environment and Capital Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy end-2025, interest-rate stabilization helped VC funding for early-stage biotech rebound ~18% YoY, increasing deal value to about $24bn and enabling smaller sponsors to advance programs into late-stage trials, boosting demand for Lonza’s CDMO services; improved equity and IPO activity (global biotech IPO proceeds up ~40% in 2025) expands addressable market; Lonza closely tracks these liquidity and macro indicators to model capacity needs and drive targeted capital expenditure for facility expansions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary Pressures and Operational Cost Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePersistent inflation in energy and raw materials—energy costs rose ~12% globally in 2023 and specialty chemical input prices remained elevated into 2024—push Lonza to adopt robust price-escalation clauses in long-term contracts to protect margins.\u003c\/p\u003e\n\u003cp\u003eLonza leverages scale and procurement expertise; the company reported adjusted EBITDA margin of 24.5% in FY 2023, helping absorb input-cost shocks through supplier negotiations and volume purchasing.\u003c\/p\u003e\n\u003cp\u003eEfficient resource management and CAPEX toward cost-effective technologies, including ongoing investments in process intensification and automation, are central to preserving profitability amid sustained high operating costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Volatility and the Swiss Franc\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs a Swiss-headquartered company with global revenues, Lonza is highly sensitive to Swiss franc strength versus the US dollar and euro; a 10% franc appreciation vs the dollar in 2023 would have materially reduced reported USD revenues given ~50% of sales invoiced in USD (2024 annual report context).\u003c\/p\u003e\n\u003cp\u003eExchange-rate swings affect competitiveness of Swiss production sites versus EU and US plants, potentially compressing margins when CHF is strong against EUR and USD.\u003c\/p\u003e\n\u003cp\u003eLonza uses sophisticated hedging—forward contracts and options—and reported net currency hedges covering a significant portion of expected 12‑18 months FX exposure, while its diversified footprint across US, EU and APAC mitigates translation risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShift Toward Outsourcing as a Cost-Optimization Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLarge pharma increasingly shifts from fixed internal manufacturing to variable-cost outsourcing; global biotech CMO market grew ~8% CAGR to an estimated $81B in 2024, driving demand for external capacity.\u003c\/p\u003e\n\u003cp\u003eThis reduces capital intensity for pharma, letting firms reallocate spend to R\u0026amp;D and marketing—Big Pharma outsourcing now accounts for roughly 40–50% of biologics manufacturing spend in 2023–24.\u003c\/p\u003e\n\u003cp\u003eLonza leverages this trend as an integrated partner covering discovery through commercial scale, reporting 2024 CDMO-related revenue growth and capacity expansions that align with rising outsourced demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCMO market ~ $81B in 2024, ~8% CAGR\u003c\/li\u003e\n\u003cli\u003eOutsourced biologics ~40–50% of manufacturing spend\u003c\/li\u003e\n\u003cli\u003eLonza expanding CDMO capacity; revenue growth tied to outsourcing trend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging Market Growth and Healthcare Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEconomic expansion in emerging markets, especially Asia (projected 4.5% GDP growth in 2025 for emerging Asia) and parts of Latin America, is boosting demand for high-quality biologics and nutrition, with biologics market CAGR ~10–12% through 2028; Lonza benefits as addressable markets expand with rising healthcare spend.\u003c\/p\u003e\n\u003cp\u003eInvestments in healthcare infrastructure and insurance (Asia health expenditure per capita up ~6% CAGR 2020–2025) enlarge opportunities for Lonza’s clients; Lonza’s global footprint enables local support and faster market entry.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEmerging Asia GDP growth ~4.5% (2025 est)\u003c\/li\u003e\n\u003cli\u003eBiologics market CAGR ~10–12% to 2028\u003c\/li\u003e\n\u003cli\u003eHealth spend per capita growth ~6% CAGR (2020–25)\u003c\/li\u003e\n\u003cli\u003eLonza global manufacturing + regional support drives client access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLonza poised to ride biotech outsourcing boom—strong margins, $24bn VC tailwinds\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic tailwinds: biotech VC deal value ~$24bn (2025), global CMO market ~$81bn (2024, ~8% CAGR), biologics market CAGR 10–12% to 2028, emerging Asia GDP ~4.5% (2025), energy costs +12% (2023); Lonza margin resilience: adj. EBITDA 24.5% (FY2023); FX exposure hedged for 12–18 months; capacity expansion aligned to outsourcing trend.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVC deal value (2025)\u003c\/td\u003e\n\u003ctd\u003e$24bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO market (2024)\u003c\/td\u003e\n\u003ctd\u003e$81bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. EBITDA (FY2023)\u003c\/td\u003e\n\u003ctd\u003e24.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmerging Asia GDP (2025)\u003c\/td\u003e\n\u003ctd\u003e4.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eLonza Group PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Lonza Group PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic or investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751837151609,"sku":"lonza-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/lonza-pestle-analysis.png?v=1772235207","url":"https:\/\/growthsharematrix.com\/products\/lonza-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}